Engineered immune cells aim to tame stubborn autoimmune diseases
NCT ID NCT06680388
First seen Jan 03, 2026 · Last updated May 16, 2026 · Updated 22 times
Summary
This early-stage study tests a personalized cell therapy (CD19 CAR-T) in 15 people with severe autoimmune diseases like lupus that haven't responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and destroy faulty B cells that drive the disease. The main goal is to check safety and find the right dose, with the hope of reducing or stopping the need for lifelong medications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese Academy of Medical Sciences Hospital of Hematology (Chinese Academy of Medical Sciences Institute of Hematology), Tianjin, 300020
RECRUITINGTianjin, Tianjin Municipality, 300020, China
Conditions
Explore the condition pages connected to this study.